Trial Profile
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; COTI 2 (Primary)
- Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Cotinga Pharmaceuticals
- 22 May 2019 According to a Cotinga Pharmaceuticals media release, the company intends to use the proceeds from the latest offering to fund this trial for COTI-2 in combination with cisplatin (solid tumors).
- 30 Jan 2019 Planned number of patients changed from 56 to 51.
- 30 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.